Company Focus
AstraZeneca
Latest AstraZeneca News
Biotechnology
The National Institute for Health and Care Excellence (NICE) has recommended two acalabrutinib-based combinations for National Health Service (NHS) use in England and Wales, Anglo-Swedish pharma major AstraZeneca announced. 6 August 2026
Related News
Insights
Company Spotlight
A San Carlos, California-based immunology biotech using nanobody-based multispecific biologics to target the IL-31 itch pathway, positioning its lead asset against the Dupixent franchise in atopic dermatitis and chronic pruritus.
Latest News & Features of interest to AstraZeneca
Pharmaceutical
China’s CSPC Pharmaceutical and UK pharma major AstraZeneca have entered into a joint venture contract in relation to the establishment of a joint venture (for the construction of a new-generation biologics manufacturing facility in Shijiazhuang, China, to further deepen their strategic collaboration. 6 August 2026
Biotechnology
US clinical-stage biotechnology company Expedition Therapeutics, which is developing novel oral small molecule therapies for inflammatory and respiratory diseases, today announced the closing of an oversubscribed $115 million Series B financing. 5 August 2026
Biotechnology
US biotech Amgen reported a 10% increase in second-quarter 2026 revenue, as growth from Repatha (evolocumab), Evenity (romosozumab) and several newer medicines outweighed declining sales of products facing pricing or biosimilar pressure. 5 August 2026
Biotechnology
US drugmaker Gilead Sciences raised the lower end of its 2026 sales guidance after second-quarter revenue beat expectations, driven by continued growth in HIV and oncology. 5 August 2026
Pharmaceutical
NHS England has recommended Procysbi (mercaptamine bitartrate [cysteamine] gastro-resistant hard capsules), also referred to as "delayed-release mercaptamine bitartrate", for routine commissioning for eligible patients aged one year and above with nephropathic cystinosis, family-controlled Italian drugmaker Chiesi revealed today. 5 August 2026
Biotechnology
Canada-based biotech Defence Therapeutics has announced a significant leadership change, appointing Dr Amie Phinney as president and chief executive (CEO), effective August 1, 2026. 4 August 2026
Biotechnology
Pathos AI, a US clinical-stage AI and technology company advancing its own pipeline of cancer therapies, announced a collaboration and co-exclusive licensing agreement with UK pharma major AstraZeneca. 4 August 2026
Biotechnology
German biotech BioNTech today reported financial results for the three and six months ended June 30, 2026 and provided an update on its corporate progress. The firm’s shares were down 3.4% at $89.11 in pre-market trading following the results. 4 August 2026
Pharmaceutical
US pharma major Pfizer raised the lower end of its full-year revenue forecast after second-quarter sales and adjusted earnings exceeded analyst expectations, with growth across its non-COVID portfolio offsetting sharp declines for Paxlovid (ritonavir) and Comirnaty. 4 August 2026
Pharmaceutical
German pharma and crop science major Bayer posted second-quarter 2026 sales of 10.87 billion euros ($12.39 billion), up 1.2% as reported and 2.2% on a currency- and portfolio-adjusted basis. Core earnings per share fell 16.7% to 0.95 euros ($1.08), held back by a normalization in tax expense and weaker earnings in the group's reconciliation line. 4 August 2026
Latest In Brief for AstraZeneca
Pharmaceutical
Codis has agreed to acquire Catalent Pharma Solutions’ Nottingham, UK, facility, expanding its contract development and manufacturing organization (CDMO) capabilities in oral solid dose development and manufacturing. The deal is expected to close in the third quarter of 2026, subject to customary conditions. 7 July 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze